TERT

Chr 5ADSomaticAR

telomerase reverse transcriptase

Also known as: CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT

The telomerase reverse transcriptase catalyzes telomere elongation by adding TTAGGG repeats to chromosome ends, functioning as the catalytic component of the telomerase ribonucleoprotein complex. Mutations cause dyskeratosis congenita and pulmonary fibrosis with bone marrow failure syndrome, inherited in both autosomal dominant and recessive patterns depending on the specific variant. This gene is highly constrained against loss-of-function variants (pLI 0.99, LOEUF 0.29), reflecting its essential role in cellular replication and survival.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt
LOFmechanismAD/Somatic/ARLOEUF 0.295 OMIM phenotypes
Clinical SummaryTERT
🧬
Gene-Disease Validity (ClinGen)
dyskeratosis congenita, autosomal dominant 2 · SDDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.99). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
36 unique Pathogenic / Likely Pathogenic· 413 VUS of 700 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — TERT
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint
0.29LOEUF
pLI 0.990
Z-score 5.24
OE 0.16 (0.090.29)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint
4.88Z-score
OE missense 0.49 (0.450.53)
350 obs / 717.6 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.16 (0.090.29)
00.351.4
Missense OE0.49 (0.450.53)
00.61.4
Synonymous OE0.98
01.21.6
LoF obs/exp: 7 / 44.8Missense obs/exp: 350 / 717.6Syn Z: 0.25
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongTERT-related dyskeratosis congenita (monoallelic)LOFAD
strongTERT-related dyskeratosis congenita (biallelic)OTHERAR
DN
0.3395th %ile
GOF
0.3689th %ile
LOF
0.67top 25%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · 1 literature citation · 72% of P/LP variants are LoF · LOEUF 0.29
GOF1 literature citation

Literature Evidence

GOFRecently, the gain-of-function mutation of the TERT promoter was identified in many types of human malignancies, and the mutated promoter acquires de novo ETS binding motifs through which the TERT transcription is activated.PMID:32768523
LOFGermline mutations in the gene encoding TERT cause haploinsufficiency with subsequent telomere shortening.PMID:32315675

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

700 submitted variants in ClinVar

Classification Summary

Pathogenic19
Likely Pathogenic17
VUS413
Likely Benign239
Conflicting1
19
Pathogenic
17
Likely Pathogenic
413
VUS
239
Likely Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
14
0
5
0
19
Likely Pathogenic
12
5
0
0
17
VUS
2
369
39
3
413
Likely Benign
0
14
47
178
239
Benign
0
0
0
0
0
Conflicting
1
Total2838891181689

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TERT · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
NASHHCCGenetic Predisposition

Evaluation of Risk of hEpatocellular Carcinoma

RECRUITING
NCT06523179Phase NAFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoStarted 2018-01-01
quantify the impact of genetic risk factors
Glioblastoma

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

ACTIVE NOT RECRUITING
NCT03491683Phase PHASE1, PHASE2Inovio PharmaceuticalsStarted 2018-05-31
INO-5401INO-9012Cemiplimab
Ganglioneuroblastoma, NodularNeuroblastoma

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

RECRUITING
NCT06172296Phase PHASE3National Cancer Institute (NCI)Started 2024-04-19
Biospecimen CollectionBone Marrow AspirationBone Marrow Biopsy
Aging

Evaluation of the Efficacy of Calcium a -Ketoglutarate(AKG-Ca) in Improving Human Aging

ACTIVE NOT RECRUITING
NCT07114536Phase NAShenzhen Hygieia Biotech Co., LtdStarted 2025-08-20
Calcium-a-ketoglutaratePlacebo(starch)
GlioblastomaGlioblastoma WHO Grade IVGlioblastoma (GBM)

CSF Proteomic Characterization of Glioblastomas

NOT YET RECRUITING
NCT06845020Univeridad Autonoma de GuadalajaraStarted 2025-03-01
Human Papilloma VirusHuman Immunodeficiency VirusAnal Intraepithelial Neoplasia

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NOT YET RECRUITING
NCT06233331Phase PHASE1Emory UniversityStarted 2026-06
Dose Level 1 ACU-D1 ointmentDose Level 2 ACU-D1 ointmentDose Level 3 ACU-D1 ointment
Urothelial Carcinoma (UC)Bladder (Urothelial, Transitional Cell) CancerLiquid Biopsy

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

RECRUITING
NCT07441499Tianjin Medical University Second HospitalStarted 2026-03
Multi-Component Liquid Biopsy for Urothelial Carcinoma
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

RECRUITING
NCT06811116Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2025-11-17
Biospecimen CollectionCabozantinib S-malateImaging Procedure
Heart FailureDilated Cardiomyopathy

Myocardial Telomere Recapping Study for Dilated Cardiomyopathy

ACTIVE NOT RECRUITING
NCT05837143Phase EARLY_PHASE1Shanghai East HospitalStarted 2023-03-30
JV001
Recurrent Malignant GliomaGlioblastomaAnaplastic Astrocytoma

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

ACTIVE NOT RECRUITING
NCT07448480Blokhin's Russian Cancer Research CenterStarted 2026-02-01
Bevacizumab-Containing RegimensNon-Bevacizumab RegimensBRAF ± MEK Targeted Therapy
Glioma

Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.

RECRUITING
NCT07077616Phase EARLY_PHASE1Biogenea Pharmaceuticals Ltd.Started 2025-07-01
Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 5 results · since 2015Search PubMed ↗